Yahoo Finance

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The American Journal of Managed Care

Acoramidis Sustains Benefits in Patients With ATTR-CM in Open-Label Extension Study

Acoramidis showed a 42% reduction in all-cause mortality and cardiovascular hospitalizations at 30 months compared to placebo in the ATTRibute-CM trial. Continuous acoramidis use resulted in a 48.2% ...
Yahoo Finance

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The American Journal of Managed Care

Acoramidis Shows Durable Benefit at 54 Months in ATTR-CM

Open-label extension data from 389 ATTRibute-CM completers compared continuous acoramidis with placebo-to-acoramidis crossover, after mandated tafamidis discontinuation. Continuous acoramidis exposure ...
Labroots

Acoramidis: A Potential Breakthrough Treatment for Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Acoramidis, an experimental medicine developed by BridgeBio Pharma, has shown promising results in a Phase 3 trial, offering new hope to patients suffering from transthyretin amyloidosis ...
Nasdaq

BridgeBio Pharma Reports Positive Phase 3 Results for Acoramidis, Highlighting Improved Survival Rates in ATTR-CM Patients

BridgeBio Pharma announced promising results from its Phase 3 trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM), revealing that early and sustained increases in serum ...
News Medical

Acoramidis shows potential to be effective, safe treatment for transthyretin amyloid cardiomyopathy

Acoramidis improves outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) compared with placebo, according to late-breaking research presented in a Hot Line session today at ESC ...
Nasdaq

BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM

The approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date In as few as 3 ...
Healio

Acoramidis may improve cardiac mass, function in transthyretin amyloid cardiomyopathy

Please provide your email address to receive an email when new articles are posted on . Cardiac MRI data suggest acoramidis could improve outcomes for people with symptomatic transthyretin amyloid ...
manilatimes

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

- ATTRibute-CM is the only study to demonstrate a direct association between a prompt, sustained increase in serum TTR and survival in patients with ATTR-CM -The open-label extension data for all ...
The Globe and Mail

Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study

-For each 5-mg/dL increase in serum TTR level within 28 days of starting treatment, the relative risk reduction of mortality was up to 31.6% through Month 30, confirming the hypothesis that ever ...